The research
object of the report is human vaccines. According to different types and
sources, vaccines can be divided into pathogenic protein vaccine, recombinant
protein vaccines, immune protein vaccines and gene vaccines.
In China,
vaccines are generally divided into Vaccine I and Vaccine II. Vaccine I is
offered for free, and it’s priced and purchased uniformly by the government,
covering the major epidemic diseases of Hepatitis B, epidemic cerebrospinal
meningitis, Tetanus, etc. Vaccine II is other vaccines inoculated voluntarily
at residents’ own expense. It is independently priced and has large profit
margins, but there are intense competition in the market. The frequently-used
Vaccine II includes Pneumonia vaccine, Varicella Vaccine, Type B Haemophilus Influenzae
Conjugate Vaccine, Influenza Vaccine, Rabies Vaccine and so on. In China,
Vaccine I market are occupied by state-owned enterprises, while foreign-funded
enterprises and private enterprises have certain advantages in Vaccine II
market.
In 2012,
the scale of Chinese vaccine market was about CNY 19 billion, while the scale
of pharmaceutical industry was about CNY 1.78 trillion in the same period. The
sales revenue of Chinese vaccine industry was only about 1% of that of the
pharmaceutical industry far below the global average level of 3%, estimated by
CRI. There is still much space for growth. China has the largest population in the
world with 10 million newborns yearly. Meanwhile, the aging of the society is
increasingly serious. With the economic development and increasingly frequent
population immigrations, it inevitably widens the spreading range and increases
the speed of disease spreading. Accordingly, new epidemic diseases (Avian
Influenza, Influenza A H1N1 and so on) occur frequently.
Data from
China’s Ministry of Health shows, in 2012, China reported 3,216,900 cases of
Class A and B infectious diseases, with16,721 dead. The reported incidence of
Class A, B infectious diseases is 238.76/0.1million and the death rate is
1.24/0.1million. In 2012, China reported 3,734,500 cases of Class C infectious
diseases, with 594 dead. The reported incidence of Class C infectious diseases is
277.18/0.1million and the death rate is 0.04/0.1 million. China’s infectious
disease incidence reflects a growing trend comparing with that in previous
years, which gradually prompts government’s attention on prevention and control
of infectious diseases and planned immunization coverage is expanding; public
awareness of vaccination is also increasing continuously which promotes the
growth of vaccine market.
In China,
there are over 30 human vaccine manufacturing enterprises with annual
production of over 1 billion including about 40 kinds of vaccines against more
than 20 kinds of viruses. With years of technological accumulation, some
private vaccine enterprises make big breakthrough in the technical fields and
Vaccine II market.
The great
potential demand of China’s human vaccine market attract many leading
enterprises of international vaccine industry to speed up the layout in China.
In 2008, Sanofi Pasteur invested USD 94 million to build vaccine factories in
Shenzhen. In 2009, Novartis bought 85% of shares of Zhejiang Tianhua Co., Ltd.
at the cost of USD 125 million which was approved in March 2011. In May 2011,
GSK ended the cooperation with Watson Biological Company; in June it bought 51%
shares of Haiwang Yingtelong Biotechnology Co., Ltd. at the cost of GBP 24
million and established wholly-owned subsidiary company. In September 2011,
GlaxoSmithKline signed contracts with Sinopharm, Shanghai Zuellig
Pharmaceutical Co., Ltd. and Beijing Keyuan Pharmaceutical Co., Ltd. The three
distributors are responsible for the business of North China, Central China and
South China respectively and provide services for customers through the cold
chain logistics system covering all over the country.
CRI
forecasts that China vaccine market will maintain a rapid growth in the future
years, but the competition will be fiercer. Some less competitive enterprises
will go bankrupt or be merged and reorganized, and the concentration rate of
vaccine market will rise continually.
Due to the
low vaccination rate in China, there’s much space for future growth. With the
increase of China’s income per capita, residents’ health awareness and their
ability to pay, the vaccine market will get more opportunities and shares.
More
following information can be acquired through this report:
- Vaccine Industry of China and the World
-Government Policies on China Vaccine Industry
-Competition in China Vaccine Market
-Major Segmentation of China Vaccine Market
- Development Trend of China Vaccine Market
Following
people are recommended to buy this report:
- Vaccine Manufacturers
- Vaccine Distributors
- Research Institutions and Investors Focusing on Vaccine Industry
Major Points in a Table of Content
Chapter 1
Basic Concept of Human Vaccine Industry
1.1 Definition
1.2 Development Course of Vaccines
1.3 Classification of Vaccines
1.4 Necessity of Vaccination
Chapter 2 Analysis on Global Vaccine Market, 2008-2012
2.1 Scale and Structure of Global Vaccine Market
2.1.1 Scale of Global Vaccine Market
2.1.2 Major Application Groups of Vaccines
2.1.3 Structure of Global Vaccine Market
2.2 Vaccines for Children
2.2.1 Major Varieties
2.2.2 Market Scale of Vaccines for Children
2.3 Vaccines for Adults
2.3.1 Varieties of Vaccines for Adults
2.3.2 Market Scale of Vaccines for Adults
Chapter 3 Development Environment of China Vaccine Industry, 2012-2013
3.1 Economic Environment
3.2 Policy Environment
3.2.1 History of China's Immunization Program
3.2.2 Procedure of Immunization Program
3.3 Relevant Legislation and Criterion of China Vaccine Industry
3.3.1 Research and Registration Stage
3.3.2 Production Stage
3.2.3 Circulation Stage
3.3.4 Supporting Policies of Chinese Government on Vaccine Industry
Chapter 4 Analysis on China's Human Vaccine Market, 2008-2012
4.1 Classification of Vaccines in China
4.2 Scale of China Vaccine Market
4.2.1 Overview
4.2.2 Structure of China Vaccine Market
4.3 Segmentation of China Vaccine Market
4.3.1 Vaccine I Market
4.3.2 Vaccine II Market
4.4 Analysis on Major Vaccines in China
4.4.1 Bacillus Calmette-Guerin
4.4.2 Poliomyelitis Vaccine
4.4.3 Measles-Mump-Rubella Vaccine
4.4.4 Diphtheria and Tetanus (DTP or DTaP) Vaccine
4.4.5 Encephalitis Vaccine
4.4.6 Meningococcus Vaccine
4.4.7 Human Rabies Vaccine
4.4.8 Type B Haemophilus Influenzae Conjugate Vaccine
4.4.9 Influenza Vaccine
4.4.10 Varicella Vaccine
4.4.11 Hepatitis A Vaccine
4.4.12 Pneumococcus Vaccine
4.4.13 Hepatitis B Vaccine
Chapter 5 China's Major Vaccine Manufacturers
5.1 China National Biotec Group (CNBG)
5.1.1 Overview
5.1.2 Subordinate Biological Products Institutions
5.2 Hualan Biological Engineering Co., Ltd.
5.3 Beijing Tiantan Biological Products Co., Ltd.
5.4 Changchun High-Tech Industry (Group) Co., Ltd.
5.5 Haiwang Yingtelong Biotechnology Co., Ltd.
5.6 Other Enterprises
Chapter 6 Prediction on Development of China Vaccine Industry
6.1 Prediction on Supply and Demand
6.1.1 Prediction on Production
6.1.2 Prediction on Market Scale
6.2 Prediction on Development Trend
6.2.1 Technology Trend
6.2.2 Market Trend
6.2.3 Competition Trend
Website:
http://www.rnrmarketresearch.com
